Trial
NCT05619172
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
SOTIO Biotech AG
Collaborators
—
Condition
Colorectal Cancer
Intervention
Nanrilkefusp alfa
Why stopped
Due to lack of efficacy shown at the time of the interim analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-24